Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?

Bone. 2000 Dec;27(6):765-8. doi: 10.1016/s8756-3282(00)00399-9.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aged
  • Alendronate / therapeutic use*
  • Calcitriol / therapeutic use
  • Calcium Channel Agonists / therapeutic use
  • Calcium Channel Blockers / therapeutic use
  • Estrogen Antagonists / pharmacology
  • Etidronic Acid / analogs & derivatives
  • Etidronic Acid / therapeutic use
  • Female
  • Hip Fractures / etiology
  • Hip Fractures / prevention & control*
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal / complications
  • Osteoporosis, Postmenopausal / drug therapy*
  • Raloxifene Hydrochloride / therapeutic use
  • Risedronic Acid
  • Spinal Fractures / etiology
  • Spinal Fractures / prevention & control*

Substances

  • Calcium Channel Agonists
  • Calcium Channel Blockers
  • Estrogen Antagonists
  • Raloxifene Hydrochloride
  • Calcitriol
  • Risedronic Acid
  • Etidronic Acid
  • Alendronate